PENTACARINAT Drug Patent Profile
✉ Email this page to a colleague
When do Pentacarinat patents expire, and what generic alternatives are available?
Pentacarinat is a drug marketed by Armour Pharm and is included in one NDA.
The generic ingredient in PENTACARINAT is pentamidine isethionate. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the pentamidine isethionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pentacarinat
A generic version of PENTACARINAT was approved as pentamidine isethionate by PAI HOLDINGS on September 28th, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PENTACARINAT?
- What are the global sales for PENTACARINAT?
- What is Average Wholesale Price for PENTACARINAT?
Summary for PENTACARINAT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Patent Applications: | 2,146 |
| DailyMed Link: | PENTACARINAT at DailyMed |
US Patents and Regulatory Information for PENTACARINAT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Armour Pharm | PENTACARINAT | pentamidine isethionate | INJECTABLE;INJECTION | 073447-001 | Apr 28, 1994 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
